Edition:
United States

Acceleron Pharma Inc (XLRN.OQ)

XLRN.OQ on NASDAQ Stock Exchange Global Market

35.12USD
22 May 2018
Change (% chg)

$0.05 (+0.14%)
Prev Close
$35.07
Open
$35.14
Day's High
$35.33
Day's Low
$35.12
Volume
4,716
Avg. Vol
114,204
52-wk High
$46.51
52-wk Low
$24.48

Chart for

About

Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta... (more)

Overall

Beta: 1.42
Market Cap(Mil.): $1,636.01
Shares Outstanding(Mil.): 45.78
Dividend: --
Yield (%): --

Financials

  XLRN.OQ Industry Sector
P/E (TTM): -- 222.84 32.59
EPS (TTM): -2.61 -- --
ROI: -38.27 -7.75 12.60
ROE: -38.88 -10.55 14.49

BRIEF-Acceleron Begins Phase 2 Trial Of Pulmonary Arterial Hypertension Treatment

* ACCELERON ANNOUNCES INITIATION OF PULSAR PHASE 2 TRIAL OF SOTATERCEPT IN PULMONARY ARTERIAL HYPERTENSION

7:07am EDT

BRIEF-Acceleron Reports Q1 Loss Per Share $0.58

* ACCELERON REPORTS FIRST QUARTER 2018 OPERATING AND FINANCIAL RESULTS

May 08 2018

BRIEF-Acceleron Receives FDA Fast Track Designation For Ace-083 In Facioscapulohumeral Muscular Dystrophy

* ACCELERON RECEIVES FDA FAST TRACK DESIGNATION FOR ACE-083 IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) Source text for Eikon: Further company coverage:

May 01 2018

BRIEF-Acceleron Pharma Q4 Loss Per Share $‍0.62​

* ACCELERON REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING AND FINANCIAL RESULTS

Feb 27 2018

BRIEF-Acceleron plans to initiate part 2 of ACE-083 FSHD phase 2 trial during Q2 of 2018

* ACCELERON PHARMA INC - PLANS TO INITIATE PART 2 OF ACE-083 FSHD PHASE 2 TRIAL DURING Q2 OF 2018

Jan 08 2018

BRIEF-BioAg Alliance Announces Updated Research And Development Pipeline

* BIOAG ALLIANCE - ANNOUNCED UPDATED RESEARCH AND DEVELOPMENT PIPELINE

Jan 04 2018

Earnings vs. Estimates